Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 12/20 | 0.61 |
| ▸ | MMP2 | P08253 | 6/20 | 0.61 |
| ▸ | MMP13 | P45452 | 7/20 | 0.58 |
| ▸ | MMP8 | P22894 | 2/20 | 0.58 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 5/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640686 | 1.00 | MMP9 (0.61) | MMP9MMP2MMP13MMP8ADAMTS4 | |
| SCHEMBL13640680 | 0.93 | MMP9 (0.54) | MMP9MMP2MMP13MMP8ADAMTS4 | |
| SCHEMBL13640690 | 0.93 | MMP9 (0.54) | MMP9MMP2MMP13MMP8ADAMTS4 | |
| SCHEMBL13640656 | 0.90 | MMP9 (0.54) | MMP9MMP2MMP13MMP8ADAMTS4 | |
| SCHEMBL13640693 | 0.90 | MMP9 (0.54) | MMP9MMP2MMP13MMP8ADAMTS4 | |
| SCHEMBL13639210 | 0.90 | MMP9 (0.77) | MMP9MMP2MMP13MMP8MMP1 | |
| SCHEMBL13639200 | 0.90 | MMP9 (0.77) | MMP9MMP2MMP13MMP8MMP1 | |
| SCHEMBL13640745 | 0.86 | MMP9 (0.81) | MMP9MMP2MMP13MMP8ADAMTS4 | |
| SCHEMBL13640715 | 0.86 | MMP9 (0.81) | MMP9MMP2MMP13MMP8ADAMTS4 | |
| SCHEMBL13640685 | 0.85 | MMP9 (0.65) | MMP9MMP2MMP13MMP8ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120282180-A1 | Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282180-A1 | Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof | MMP1, MMP17, MMP25 | MMP9 4/4885MMP2 16/4885MMP13 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.